Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Equity Average (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Equity Average data on record, last reported at $4.8 million in Q3 2025.

  • For Q3 2025, Equity Average fell 53.58% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $4.8 million, down 53.58%, while the annual FY2024 figure was $10.0 million, 36.68% down from the prior year.
  • Equity Average reached $4.8 million in Q3 2025 per GANX's latest filing, up from $4.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $42.9 million in Q2 2021 and bottomed at $4.7 million in Q2 2025.
  • Average Equity Average over 5 years is $18.8 million, with a median of $13.1 million recorded in 2023.
  • Peak YoY movement for Equity Average: surged 21236.09% in 2021, then plummeted 62.92% in 2023.
  • A 5-year view of Equity Average shows it stood at $36.2 million in 2021, then tumbled by 42.59% to $20.8 million in 2022, then plummeted by 52.08% to $10.0 million in 2023, then fell by 18.38% to $8.1 million in 2024, then crashed by 40.89% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $4.8 million in Q3 2025, $4.7 million in Q2 2025, and $6.6 million in Q1 2025.